Oct 25, 2017
Patients with non-cystic fibrosis bronchiectasis (NCFBE), a
progressive pulmonary disease, currently have no treatment options
in the US. Nancy Pecota, CFO of Aradigm
Corporation, discusses NCFBE and what Aradigm is doing to help
these patients and possibly others who have an un-diagnosed
condition . Their inhalable drug Linhaliq™ is currently on the fast
track for FDA approval for NCFBE. Nancy discusses Aradigm’s
progress to provide an effective treatment option
and prevent future infections in
these patients.
#bronchiectasis #NCFBE #Linhaliq #Aradigm #pulmonarydisease